Treat-to-Target in CD


Miguel Regueiro, MD, and David Rubin, MD, review the treat-to-target strategy in relation to CD management, and how treat-to-target moves beyond symptom control.

This is a video synopsis/summary of a panel discussion involving Marla Dubinsky, MD; David Rubin, MD; Miguel Regueiro, MD; Remo Panaccione, MD, FRCPC; and Sara Horst, MD, MPH.

The experts discuss the evolving approach to treating Crohn's disease, emphasizing the importance of symptom control for patients who have been suffering. The immediate goal is to improve patients' well-being and allow them to live their lives without focusing solely on long-term treatment strategies like "treat to target."

The conversation addresses the historical progression in treatment goals, from focusing solely on symptom control to incorporating biomarkers such as C-reactive protein and fecal calprotectin. The panel acknowledges the constant evolution in setting treatment goals, moving towards more comprehensive measures like endoscopy and cross-sectional imaging, including ultrasound.

The speakers highlight the challenge of communicating the concept of treat to target to patients and colleagues, noting that the term "stride" may not be familiar to patients. The discussion revolves around educating patients about the evolution of treatment goals and the importance of addressing various aspects of the disease, including perianal disease, joint pain, fatigue, and inflammatory markers.

A scorecard analogy is introduced, with each aspect of the disease considered as a point that needs to be addressed. The "treat to target" strategy aims to decrease these points, bringing patients as close to normal as possible. The speakers emphasize the need for clear communication with patients, avoiding medical jargon, and focusing on collaborative efforts to achieve treatment goals.

The conversation concludes by underlining the importance of a follow-up plan and a clear cadence of moving forward. The treat-to-target strategy is portrayed as a collaborative effort between healthcare providers and patients to improve quality of life by abrogating inflammation and preventing complications. The emphasis remains on maintaining a balance between immediate symptom relief and achieving long-term treatment goals.

Video synopsis is AI-generated and reviewed by HCPLive editorial staff.

Related Videos
4 KOLs are featured in this series
Sorana Segal-Maurer, MD, an expert on HIV
Sorana Segal-Maurer, MD, an expert on HIV
4 KOLs are featured in this series
Video 4 - Featuring 3 KOLs in, "Implementing Treat to Target in the Long-term in Inflammatory Bowel Disease "
Video 3 - Featuring 3 KOLs in, "How important is transmural healing as a treatment target in UC and CD?   Where does intestinal ultrasound fit in CD management?  "
A panel of 4 experts on asthma
Shauna Applin, ARNP, an expert on HIV
4 KOLs are featured in this series
4 KOLs are featured in this series
© 2024 MJH Life Sciences

All rights reserved.